Search

Your search keyword '"Dixon, Chantel"' showing total 8 results
Start Over Author "Dixon, Chantel"
8 results on '"Dixon, Chantel"'

1. Supplementary Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Author

Aranda-Orgilles, Beatriz, primary, Chion-Sotinel, Isabelle, primary, Skinner, Jordan, primary, Grudman, Steven, primary, Mumford, Ben, primary, Dixon, Chantel, primary, Postigo Fernandez, Jorge, primary, Erler, Piril, primary, Duchateau, Phillipe, primary, Gouble, Agnes, primary, Galetto, Roman, primary, and Poirot, Laurent, primary

Published
2023
Full Text
View/download PDF

2. Data from Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Author

Aranda-Orgilles, Beatriz, primary, Chion-Sotinel, Isabelle, primary, Skinner, Jordan, primary, Grudman, Steven, primary, Mumford, Ben, primary, Dixon, Chantel, primary, Postigo Fernandez, Jorge, primary, Erler, Piril, primary, Duchateau, Phillipe, primary, Gouble, Agnes, primary, Galetto, Roman, primary, and Poirot, Laurent, primary

Published
2023
Full Text
View/download PDF

3. Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Author

Aranda-Orgilles, Beatriz, primary, Chion-Sotinel, Isabelle, additional, Skinner, Jordan, additional, Grudman, Steven, additional, Mumford, Ben, additional, Dixon, Chantel, additional, Postigo Fernandez, Jorge, additional, Erler, Piril, additional, Duchateau, Phillipe, additional, Gouble, Agnes, additional, Galetto, Roman, additional, and Poirot, Laurent, additional

Published
2023
Full Text
View/download PDF

4. 217 Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth

Author

Erler, Piril, primary, Kurcon, Tomasz, additional, Skinner, Jordan, additional, Dixon, Chantel, additional, Grudman, Steven, additional, Mumford, Ben, additional, Das, Shipra, additional, Boyne, Alexander, additional, Juillerat, Alexandre, additional, Galetto, Roman, additional, Valton, Julien, additional, Cho, Hana, additional, Poirot, Laurent, additional, and Aranda-Orgilles, Beatriz, additional

Published
2022
Full Text
View/download PDF

6. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition

Author

Dey, Joyoti, primary, Deckwerth, Thomas L., additional, Kerwin, William S., additional, Casalini, Joseph R., additional, Merrell, Angela J., additional, Grenley, Marc O., additional, Burns, Connor, additional, Ditzler, Sally H., additional, Dixon, Chantel P., additional, Beirne, Emily, additional, Gillespie, Kate C., additional, Kleinman, Edward F., additional, and Klinghoffer, Richard A., additional

Published
2017
Full Text
View/download PDF

8. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer.

Author

Erler, Piril, Kurcon, Tomasz, Cho, Hana, Skinner, Jordan, Dixon, Chantel, Grudman, Steven, Rozlan, Sandra, Dessez, Emilie, Mumford, Ben, Jo, Sumin, Boyne, Alex, Juillerat, Alexandre, Duchateau, Philippe, Poirot, Laurent, and Aranda-Orgilles, Beatriz

Subjects
*TRIPLE-negative breast cancer, *CHIMERIC antigen receptors, *T cells
Abstract

Solid tumors, such as triple-negative breast cancer (TNBC), are biologically complex due to cellular heterogeneity, lack of tumor-specific antigens, and an immunosuppressive tumor microenvironment (TME). These challenges restrain chimeric antigen receptor (CAR) T cell efficacy, underlining the importance of armoring. In solid cancers, a localized tumor mass allows alternative administration routes, such as intratumoral delivery with the potential to improve efficacy and safety but may compromise metastatic-site treatment. Using a multi-layered CAR T cell engineering strategy that allowed a synergy between attributes, we show enhanced cytotoxic activity of MUC1 CAR T cells armored with PD1KO, tumor-specific interleukin-12 release, and TGFBR2KO attributes catered towards the TNBC TME. Intratumoral treatment effectively reduced distant tumors, suggesting retention of antigen-recognition benefits at metastatic sites. Overall, we provide preclinical evidence of armored non-alloreactive MUC1 CAR T cells greatly reducing high TNBC tumor burden in a TGFB1-and PD-L1- rich TME both at local and distant sites while preserving safety. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results